Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia

To the editor: Whether, and for which patients with acute myeloid leukemia, the dose of daunorubicin in induction should be 90 mg/m2 continues to be discussed. There seems little doubt that 90 mg/m2 is superior to a 45 mg/m2 dose.[1][1][⇓][2]-[3][3] In this context, the reports from the Eastern